Related Experiment Video
Updated: May 17, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[Prostate carcinoma with squamous differentiation after combination endocrine therapy: a case report]
Takao Nagashima1, Mako Niiro, Kifu Hirayama
1The Department of Urology, Nagahama City Kohoku Hospital.
Hinyokika Kiyo. Acta Urologica Japonica
|October 12, 2012
Summary
A rare case of squamous cell prostate carcinoma emerged after standard prostate adenocarcinoma treatment. This aggressive cancer subtype requires alternative chemotherapy strategies post-surgery.
Area of Science:
- Urology
- Oncology
- Pathology
Background:
- Prostate adenocarcinoma is the most common cancer in men.
- Endocrine therapy is a standard treatment for advanced prostate cancer.
- Rarely, prostate cancer can transform into other histological subtypes.
Observation:
- A 68-year-old man with advanced prostate adenocarcinoma (Gleason score 8) received combination endocrine therapy.
- Following treatment, radical prostatectomy revealed a rare squamous cell carcinoma of the prostate.
- The patient's initial presentation included microscopic hematuria and a PSA level of 7.06 ng/ml.
Findings:
- Histopathological examination confirmed squamous cell carcinoma with residual adenocarcinoma.
- The patient was switched to combination chemotherapy (docetaxel, cisplatin, 5-FU) post-surgery.
- No distant metastasis was observed 18 months after surgical intervention.
Implications:
- This case highlights the potential for histological transformation in prostate cancer under therapy.
- It underscores the importance of vigilant monitoring and reassessment of treatment strategies.
- Further research is needed to understand the mechanisms and optimal management of therapy-induced prostate cancer subtype conversion.
